Department of Radiology

Publications

2019

Kim E, Mema E, Axelrod D, Sigmund E, Kim SG, Babb J, et al. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer. Eur J Radiol. 2019;110:163-168.

Qiu W, Li D, Jin X, Liu F, Nguyen TD, Prince MR, et al. Sliding motion compensated low-rank plus sparse (SMC-LS) reconstruction for high spatiotemporal free-breathing liver 4D DCE-MRI. Magn Reson Imaging. 2019;58:56-66.

Zhang S, Liu Z, Nguyen TD, Yao Y, Gillen KM, Spincemaille P, et al. Clinical feasibility of brain quantitative susceptibility mapping. Magn Reson Imaging. 2019;60:44-51.

Parker DB, Razlighi QR. The Benefit of Slice Timing Correction in Common fMRI Preprocessing Pipelines. Front Neurosci. 2019;13:821.

Jafari R, Sheth S, Spincemaille P, Nguyen TD, Prince MR, Wen Y, et al. Rapid automated liver quantitative susceptibility mapping. J Magn Reson Imaging. 2019;50(3):725-732.

Miyata M, Kakeda S, Toyoshima Y, Ide S, Okada K, Adachi H, et al. Potential usefulness of signal intensity of cerebral gyri on quantitative susceptibility mapping for discriminating corticobasal degeneration from progressive supranuclear palsy and Parkinson's disease. Neuroradiology. 2019;61(11):1251-1259.

Amor-Coarasa A, Kelly JM, Singh PK, Ponnala S, Nikolopoulou A, Williams C, et al. [F]Fluoroethyltriazolyl Monocyclam Derivatives as Imaging Probes for the Chemokine Receptor CXCR4. Molecules. 2019;24(8).

Reyes-Madrigal F, León-Ortiz P, Mao X, Mora-Durán R, Shungu DC, de la Fuente-Sandoval C. Striatal Glutathione in First-episode Psychosis Patients Measured In Vivo with Proton Magnetic Resonance Spectroscopy. Arch Med Res. 2019;50(4):207-213.

Zhang J, Kim SG. Estimation of cellular-interstitial water exchange in dynamic contrast enhanced MRI using two flip angles. NMR Biomed. 2019;32(11):e4135.

Pandit-Taskar N, Zanzonico PB, Kramer K, Grkovski M, Fung EK, Shi W, et al. Biodistribution and Dosimetry of Intraventricularly Administered I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. J Nucl Med. 2019;60(12):1794-1801.